LIVZON PHARMAC. GRP H YC1

Research LIVZON PHARMAC. GRP H YC1 (LP6) on Bullrun: valuation model: 19.1% undervalued, market cap EUR 2.52B, P/E 9.8, dividend yield 7.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerLP6
ExchangeF
CountryChina
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CurrencyEUR
Valuation signal19.1% undervalued
Market capEUR 2.52B
P/E9.8
Dividend yield7.0%
Financial periodQ1 2026
RevenueEUR 2.87B
Net incomeEUR 576.91M
Free cash flowEUR 727.35M
Gross margin65.9%

Valuation Snapshot

Bullrun's latest valuation model marks LIVZON PHARMAC. GRP H YC1 as 19.1% undervalued; latest market cap is EUR 2.52B; P/E is 9.8; dividend yield is 7.0%.

About LIVZON PHARMAC. GRP H YC1

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field;

Frequently asked questions

Is LIVZON PHARMAC. GRP H YC1 overvalued or undervalued?

Bullrun's valuation model currently marks LIVZON PHARMAC. GRP H YC1 as 19.1% undervalued.

What is LIVZON PHARMAC. GRP H YC1's market cap?

LIVZON PHARMAC. GRP H YC1's market capitalization is EUR 2.52B.

What is LIVZON PHARMAC. GRP H YC1's P/E ratio?

LIVZON PHARMAC. GRP H YC1's price-to-earnings (P/E) ratio is 9.8.

Does LIVZON PHARMAC. GRP H YC1 pay a dividend?

LIVZON PHARMAC. GRP H YC1 has a dividend yield of 7.0%.